Quick Answer
Jazz Pharmaceuticals plc reported Cash And Cash Equivalents At Carrying Value of $1.39 billion for the year ending 2025.
- Jazz Pharmaceuticals plc showed a decrease of -42.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Jazz Pharmaceuticals plc's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $9.57 million | Q3 2010: $22.85 million | Q1 2011: $65.06 million | Q2 2011: $102.40 million | Q3 2011: $101.22 million | Q1 2012: $170.65 million | Q2 2012: $154.54 million | Q3 2012: $189.79 million | Q1 2013: $450.51 million | Q2 2013: $504.31 million | Q3 2013: $588.46 million | Q1 2014: $245.87 million | Q2 2014: $268.26 million | Q3 2014: $575.04 million | Q1 2015: $782.60 million | Q2 2015: $921.64 million | Q3 2015: $998.86 million | Q1 2016: $979.78 million | Q2 2016: $867.97 million | Q3 2016: $366.57 million | Q1 2017: $347.00 million | Q2 2017: $239.21 million | Q3 2017: $252.62 million | Q1 2018: $453.17 million | Q2 2018: $485.08 million | Q3 2018: $499.02 million | Q1 2019: $547.47 million | Q2 2019: $637.74 million | Q3 2019: $795.18 million | Q1 2020: $701.60 million | Q2 2020: $786.08 million | Q3 2020: $741.94 million | Q1 2021: $2.10 billion | Q2 2021: $891.40 million | Q3 2021: $671.78 million | Q1 2022: $490.84 million | Q2 2022: $711.27 million | Q3 2022: $839.36 million | Q1 2023: $1.17 billion | Q2 2023: $1.28 billion | Q3 2023: $1.34 billion | Q1 2024: $1.44 billion | Q2 2024: $1.36 billion | Q3 2024: $2.22 billion | Q1 2025: $1.86 billion | Q2 2025: $1.19 billion | Q3 2025: $1.33 billion.
- Over the full 18 years of available data (2008 to 2025), Jazz Pharmaceuticals plc's Cash And Cash Equivalents At Carrying Value has grown by 5,489.3%.
- Historical annual values: Fiscal year 2025: $1.39 billion | Fiscal year 2024: $2.41 billion | Fiscal year 2023: $1.51 billion | Fiscal year 2022: $881.48 million | Fiscal year 2021: $591.45 million | Fiscal year 2020: $1.06 billion | Fiscal year 2019: $637.34 million | Fiscal year 2018: $309.62 million | Fiscal year 2017: $386.04 million | Fiscal year 2016: $365.96 million | Fiscal year 2015: $988.79 million | Fiscal year 2014: $684.04 million | Fiscal year 2013: $636.50 million | Fiscal year 2012: $387.20 million | Fiscal year 2011: $82.08 million | Fiscal year 2010: $44.79 million | Fiscal year 2009: $15.60 million | Fiscal year 2008: $24.90 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: